{Reference Type}: Journal Article
{Title}: [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
{Author}: Müller AC;van Oorschot B;Micke O;Guckenberger M;
{Journal}: Strahlenther Onkol
{Volume}: 194
{Issue}: 1
{Year}: 01 2018
{Factor}: 4.033
{DOI}: 10.1007/s00066-017-1185-y
{Abstract}: We aim to introduce and discuss the statements and recommendations of the German S3 guideline on renal cell cancer for daily practice of radiation oncologists.<BR>This report comprises indication, treatment decision, dose prescription and current literature including treatment of oligometastatic disease.<BR>According to different stages of the disease and the structure of the guideline we focus on five treatment situations and recommendations for decision making: (1) Neo-/adjuvant treatment before or after nephrectomy: No indication for radiotherapy. (2) Small renal mass: Stereotactic ablative radiotherapy is currently seen as experimental option due to small patient numbers reported in the literature. However, local tumor control achieved by SBRT appears favourable with >90% at 2 years. (3) Oligometastasis: Radiation treatment with higher local doses or stereotactic treatment is possible after interdisciplinary discussion. Indications for palliative (4) and symptomatic treatment (5) are not different compared to other tumor entities.<BR>Currently, there is no evidence-based indication for radiation treatment in the primary setting (adjuvant/neoadjuvant or definitive) of renal cell cancer. In the future stereotactic radiotherapy should have a stronger role in the treatment of medically inoperable patients with primary renal cell cancer and especially in the setting of oligometastasis.